Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q3- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
administered, advertising, Boston, clearance, CLIA, CMS, contemplated, difficult, distribution, divert, diverting, draft, efficacy, effort, EU, Europe, exit, experience, FDA, focused, footprint, framework, grounded, guidance, infringement, Inova, instituted, IVDR, ix, labeling, LDT, legislation, legislative, letter, literature, lost, noncompliance, object, oversight, patent, pendency, percent, Permission, pharmacogenetic, Phase, policy, preclinical, proposed, quality, Ravgen, reaction, refrain, registration, satisfaction, scientific, sound, surveillance, systematic, timeline, Trademark, ultimate, unexpected, vandalism, vi, vii, viii, vitro, warning, Western, xi, xii
Removed:
conclusion, evaluate, initiated, invest, profitable, review, team, therapeutic
Valuein 2021 Q3 filing- Value in 2022 Q2 filing
Original filings
Filing view